005250.KS

Green Cross Holdings Corporation [005250.KS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

005250.KS Stock Summary

Top 10 Correlated ETFs

005250.KS

Top 10 Correlated Stocks

005250.KS

In the News

005250.KS Financial details

Company Rating
-
Market Cap
717.6B
Income
-66.57B
Revenue
2057.94B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
165
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-23.87
Forward P/E
-
PEG
1.12
P/S
0.35
P/B
0.71
P/C
-
P/FCF
-3.5
Quick Ratio
-
Current Ratio
0.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.47K
EPS next Y
-
EPS next Q
-
EPS this Y
-191.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.18%
Revenue last 5Y
6.18%
Revenue Q/Q
-0.03%
EPS Q/Q
13.13%
-
-
-
-
SMA20
1.86%
SMA50
-4.72%
SMA100
-7.78%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-3%
ROC
-0.01%
Gross Margin
30%
Oper. Margin
-1%
Profit Margin
-1%
Payout
-104%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
12920.0-17990.0
52W High
-22.18%
52W Low
+8.36%
RSI
62.64
Rel Volume
0.83
Avg Volume
62.41K
Volume
52.01K
Perf Week
5.66%
Perf Month
-0.92%
Perf Quarter
-13.69%
Perf Half Y
-11%
-
-
-
-
Beta
0.934
-
-
Volatility
185.54%, 466.96%
Prev Close
0.94%
Price
14000
Change
1.38%

Something similar

Top by Market Cap
BRK-A
META
VTI
TL0.DE
0YXG.L
Top Correlated ETFs
252650.KS
252000.KS
307520.KS
315270.KS
290080.KS
Top Correlated Stocks
071840.KS
00279K.KS
120110.KS
006200.KS
010060.KS
Similar Market Cap
2579.T
601138.SS
VTBR.ME
2891.TW
4021.T

Company Profile

Healthcare Biotechnology
  • Volume Average 62.41K
  • Market Capitalization 717.6B
  • Employee 165
  • CEO Mr. Il-Sup Huh Ph.D.
  • Headquarters Yongin-Si,KR
  • IPO Date 2000-01-04
  • Website https://www.greencross.com

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.